2seventy Bio, Inc.
https://www.2seventybio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From 2seventy Bio, Inc.
Adaptimmune Starts Planning TCR Commercialization For An Ultra Rare Patient Population
CEO Adrian Rawcliffe talked with Scrip about filing and early commercial plans for afami-cel in synovial carcinoma if it is approved by the FDA.
Bluebird Could Find US Tailwind For Zynteglo After ICER Report
The cost-effectiveness watchdog now assumes an upfront $2.1m payment instead of five annual payments. The company switched gears to the US after the TDT gene therapy stumbled in Europe.
Janssen Seeking Medicare Add-On Payments For CAR-T Carvykti, But CMS May Be Skeptical
J&J will need to convince the Centers for Medicare and Medicaid Services that its treatment is not substantially similar to existing CAR-T’s in order to qualify for supplemental Medicare reimbursement.
J&J Continues Signaling Aggressive M&A Approach To Drive Growth
Johnson & Johnson reported disappointing Q1 sales for its COVID-19 vaccine but called the Carvykti launch solid and discussed plans for further diversification of its multiple myeloma portfolio.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy